Search Results - "ARLEN, Philip"

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial by Madan, Ravi A, MD, Mohebtash, Mahsa, MD, Arlen, Philip M, MD, Vergati, Matteo, MD, Rauckhorst, Myrna, RN, Steinberg, Seth M, PhD, Tsang, Kwong Y, PhD, Poole, Diane J, Parnes, Howard L, MD, Wright, John J, MD PhD, Dahut, William L, MD, Schlom, Jeffrey, PhD, Gulley, James L, Dr

“…Summary Background Therapeutic cancer vaccines have shown activity in metastatic castration-resistant prostate cancer (mCRPC), and methods are being assessed…”
Get full text

Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells by Fantini, Massimo, Tsang, Kwong Y, Arlen, Philip M

“…Cancer vaccines stimulate the activation of specific humoral and cellular adaptive responses against cancer cells.Antibodies generated post vaccination can be…”
Get full text

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer by KANTOFF, Philip W, SCHUETZ, Thomas J, DAHUT, William L, ARLEN, Philip M, GULLEY, James L, GODFREY, Wayne R, BLUMENSTEIN, Brent A, GLODE, L. Michael, BILHARTZ, David L, WYAND, Michael, MANSON, Kelledy, PANICALI, Dennis L, LAUS, Reiner, SCHLOM, Jeffrey

“…Therapeutic prostate-specific antigen (PSA) -targeted poxviral vaccines for prostate cancer have been well tolerated. PROSTVAC-VF treatment was evaluated for…”
Get full text

Machine Evaluation of Catchment Area Relevance through Text Mining by Arlen, Philip A, Chakko, Joseph, DeGennaro, Geoffrey, Kobetz, Erin, Mahal, Brandon

“…The University of Miami Sylvester Comprehensive Cancer Center Community Outreach and Engagement Office has developed an algorithm to aid in identifying…”
Get more information

Cancer Vaccines: Moving Beyond Current Paradigms by SCHLOM, Jeffrey, ARLEN, Philip M, GULLEY, James L

“…The field of cancer vaccines is currently in an active state of preclinical and clinical investigations. Although no therapeutic cancer vaccine has to date…”
Get full text

Neoantigens in the immuno-oncology space by Arlen, Philip M

“…Alterations in the tumor DNA occur during the development and progression of cancer. Since these antigens are considered foreign to the immune system, the host…”
Get full text

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer by Madan, Ravi A, Arlen, Philip M, Mohebtash, Mahsa, Hodge, James W, Gulley, James L

“…Prostvac is a prostate cancer vaccine regimen consisting of a recombinant vaccinia vector as a primary vaccination, followed by multiple booster vaccinations…”
Get more information

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury by Heery, Christopher R, Singh, B Harpreet, Rauckhorst, Myrna, Marté, Jennifer L, Donahue, Renee N, Grenga, Italia, Rodell, Timothy C, Dahut, William, Arlen, Philip M, Madan, Ravi A, Schlom, Jeffrey, Gulley, James L

“…The nuclear transcription factor brachyury has previously been shown to be a strong mediator of the epithelial-to-mesenchymal transition (EMT) in human…”
Get more information

Effective Plague Vaccination via Oral Delivery of Plant Cells Expressing F1-V Antigens in Chloroplasts by Arlen, Philip A, Singleton, Michael, Adamovicz, Jeffrey J, Ding, Yi, Davoodi-Semiromi, Abdolreza, Daniell, Henry

“…The chloroplast bioreactor is an alternative to fermentation-based systems for production of vaccine antigens and biopharmaceuticals. We report here expression…”
Get full text

Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas by Tsang, Kwong yok, Fantini, Massimo, Mavroukakis, Sharon A., Zaki, Anjum, Annunziata, Christina M., Arlen, Philip M.

“…NEO-201 is an IgG1 humanized monoclonal antibody (mAb) that binds to tumor-associated variants of carcinoembryonic antigen-related cell adhesion molecule…”
Get full text

Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer by Madan, Ravi A, Bilusic, Marijo, Stein, Mark N, Donahue, Renee N, Arlen, Philip M, Karzai, Fatima, Plimack, Elizabeth, Wong, Yu-Ning, Geynisman, Daniel M, Zibelman, Matthew, Mayer, Tina, Strauss, Julius, Chen, Gang, Rauckhorst, Myrna, McMahon, Sheri, Couvillon, Anna, Steinberg, Seth, Figg, William D, Dahut, William L, Schlom, Jeffrey, Gulley, James L

“…Abstract Background Before 2018, there was no standard of care for non-metastatic (M0) castration resistant prostate cancer nmCRPC. Androgen receptor…”
Get full text

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma by Gulley, James L, Arlen, Philip M, Tsang, Kwong-Yok, Yokokawa, Junko, Palena, Claudia, Poole, Diane J, Remondo, Cinzia, Cereda, Vittore, Jones, Jacquin L, Pazdur, Mary P, Higgins, Jack P, Hodge, James W, Steinberg, Seth M, Kotz, Herbert, Dahut, William L, Schlom, Jeffrey

“…Purpose: Poxviral vectors have a proven safety record and can be used to incorporate multiple transgenes. Prior clinical trials with poxviral vaccines have…”
Get full text

Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy by Madan, Ravi A, Gulley, James L, Schlom, Jeffrey, Steinberg, Seth M, Liewehr, David J, Dahut, William L, Arlen, Philip M

“…Purpose: We reported previously the first randomized study of any kind in patients with nonmetastatic, castrate-resistant prostate cancer. The study employed…”
Get full text

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer by Gulley, James L, Arlen, Philip M, Madan, Ravi A, Tsang, Kwong-Yok, Pazdur, Mary P, Skarupa, Lisa, Jones, Jacquin L, Poole, Diane J, Higgins, Jack P, Hodge, James W, Cereda, Vittore, Vergati, Matteo, Steinberg, Seth M, Halabi, Susan, Jones, Elizabeth, Chen, Clara, Parnes, Howard, Wright, John J, Dahut, William L, Schlom, Jeffrey

“…A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p =…”
Get full text

Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer by Yokokawa, Junko, Cereda, Vittore, Remondo, Cinzia, Gulley, James L, Arlen, Philip M, Schlom, Jeffrey, Tsang, Kwong Y

“…CD4+CD25(high)FoxP3+ regulatory T cells (Treg) have been shown to inhibit the activation and function of T cells that participate in antigen-specific immune…”
Get full text

First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors by Cole, Christopher B, Morelli, Maria Pia, Fantini, Massimo, Miettinen, Markku, Fetsch, Patricia, Peer, Cody, Figg, William D, Yin, Tyler, Houston, Nicole, McCoy, Ann, Lipkowitz, Stanley, Zimmer, Alexandra, Lee, Jung-Min, Pavelova, Miroslava, Villanueva, Erin N, Trewhitt, Kathryn, Solarz, B Brooke, Fergusson, Maria, Mavroukakis, Sharon A, Zaki, Anjum, Tsang, Kwong Y, Arlen, Philip M, Annunziata, Christina M

“…NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1…”
Get full text

Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer by Ning, Yang-Min, Gulley, James L, Arlen, Philip M, Woo, Sukyung, Steinberg, Seth M, Wright, John J, Parnes, Howard L, Trepel, Jane B, Lee, Min-Jung, Kim, Yeong Sang, Sun, Haihao, Madan, Ravi A, Latham, Lea, Jones, Elizabeth, Chen, Clara C, Figg, William D, Dahut, William L

“…PURPOSE We previously demonstrated that thalidomide appears to add to the activity of docetaxel in metastatic castration-resistant prostate cancer (CRPC)…”
Get full text

Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma by Bilusic, Marijo, Heery, Christopher R., Arlen, Philip M., Rauckhorst, Myrna, Apelian, David, Tsang, Kwong Y., Tucker, Jo A., Jochems, Caroline, Schlom, Jeffrey, Gulley, James L., Madan, Ravi A.

“…Yeast-CEA (GI-6207) is a therapeutic cancer vaccine genetically modified to express recombinant carcinoembryonic antigen (CEA) protein, using heat-killed yeast…”
Get full text

Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer by Kim, Richard D, Azad, Nilofer S, Morse, Michael A, Poplin, Elizabeth, Mahipal, Amit, Tan, Jr, Benjamin, Mavroukakis, Sharon A, Fantini, Massimo, Tsang, Kwong Y, Zaki, Anjum, Torrealba, Jose, Arlen, Philip M, Beg, Muhammad S

“…Patients with metastatic colorectal cancer refractory to chemotherapy have limited treatment options. Ensituximab (NEO-102) is a novel chimeric mAb targeting a…”
Get full text

A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer by MOHEBTASH, Mahsa, TSANG, Kwong-Yok, STEINBERG, Seth M, PAZDUR, Mary, RAUCKHORST, Myrna, JONES, Elizabeth C, DAHUT, William L, SCHLOM, Jeffrey, GULLEY, James L, MADAN, Ravi A, HUEN, Ngar-Yee, POOLE, Diane J, JOCHEMS, Caroline, JONES, Jacquin, FERRARA, Theresa, HEERY, Christopher R, ARLEN, Philip M

“…PANVAC is a recombinant poxviral vaccine that contains transgenes for MUC-1, CEA, and 3 T-cell costimulatory molecules. This study was conducted to obtain…”
Get full text